$CUR News
Last published 5y ago
- 5y agoCURNeuroRx Announces Dosing of First Patient with ZYESAMI™ in P2/3 Clinical Study for the Treatment of Moderate and Severe COVID-19 (AVICOVID-2)GlobeNewswireRADNOR, Pa., March 19, 2021 (GLOBE NEWSWIRE) -- NeuroRx, Inc. announced the first patient in its P2/3 study of inhaled ZYESAMI™ in the treatment of moderate and severe COVID-19 (AVICOVID-2) was...
- 7y agoCURSNCASeneca Biopharma to Begin Trading Under New Ticker Symbol SNCAPR NewswireSeneca Biopharma, Inc., (Nasdaq: CUR), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need,...
- 7y agoCURSNCASeneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune DiseasesPR NewswireSeneca Biopharma, Inc., (fka Neuralstem, Inc.) (NASDAQ: CUR), a clinical-stage biopharmaceutical company developing novel treatments for diseases of...
- 7y agoCURSeneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership SummitPR NewswireSeneca Biopharma, Inc., (fka Neuralstem, Inc) (NASDAQ: CUR) a clinical-stage biopharmaceutical company developing novel treatments for diseases of...
- 7y agoCURNeuralstem Becomes Seneca BiopharmaPR NewswireNeuralstem, Inc. (NASDAQ:CUR), announces that the company has changed its name to Seneca Biopharma, Inc. The company anticipates that its shares will ...
- 7y agoCURNeuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636(c)(4)PR NewswireNeuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and...
- 7y agoCURNeuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke PatientsPR NewswireNeuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced completion...
- 7y agoCURNeuralstem Reports Second Quarter 2019 Fiscal ResultsPR NewswireNeuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and...
- 7y agoCURNeuralstem Announces Nasdaq Hearings Panel Grants Request For Continued ListingPR NewswireNeuralstem, Inc. (Nasdaq: CUR) ("Neuralstem" or the Company") today announced that on August 6, 2019, it received a letter from the Office of General ...
- 7y agoCURNeuralstem Closes $7.5 Million Underwritten Public OfferingPR NewswireNeuralstem, Inc. (Nasdaq: CUR) ("Neuralstem" or the "Company") today announced the closing of its underwritten public offering of an aggregate of...
- 7y agoCURNeuralstem Announces Pricing of $7.5 Million Underwritten Public OfferingPR NewswireNeuralstem, Inc. (Nasdaq: CUR) ("Neuralstem" or the "Company") today announced the pricing of its underwritten public offering of an aggregate of...
- 7y agoCURNeuralstem Appoints Mary Ann Gray, Ph.D., to Board of DirectorsPR NewswireNeuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and...
- 7y agoCURNeuralstem Announces a 1-for-20 Reverse Stock SplitPR NewswireNeuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, today announced a...
- 7y agoCURNeuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke PatientsPR NewswireNeuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced the...
- 13y agoHTGCOCZCTICCURHercules Technology Growth Capital Provides Investment Portfolio Update for First Quarter 2013Business WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Technology Growth Capital, Inc. (NYSE: HTGC), (“Hercules”), the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science and cleantech industries, at all stages of development, today announced its first quarter 2013 por ...